| 153.13 -4.09 (-2.6%) | 09-15 11:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 185.81 |
1-year : | 193.25 |
| Resists | First : | 159.08 |
Second : | 165.46 |
| Pivot price | 155.66 |
|||
| Supports | First : | 148.77 |
Second : | 123.78 |
| MAs | MA(5) : | 155.45 |
MA(20) : | 155.16 |
| MA(100) : | 159.52  |
MA(250) : | 146.87 |
|
| MACD | MACD : | -1.9 |
Signal : | -2.3 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 48.2 |
| RSI | RSI(14): 38.8 |
|||
| 52-week | High : | 186.11 | Low : | 122.13 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NBIX ] has closed below the lower bollinger band by 3.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NBIX ] is to continue within current trading range. It is unclear right now based on current values. 66% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 159.31 - 160.06 | 160.06 - 160.77 |
| Low: | 154.61 - 155.49 | 155.49 - 156.32 |
| Close: | 155.8 - 157.16 | 157.16 - 158.44 |
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Mon, 14 Sep 2026
Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale - Stock Titan
Mon, 14 Sep 2026
Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale - Stock Titan
Mon, 14 Sep 2026
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring A 34.93% Potential Upside - DirectorsTalk Interviews
Mon, 07 Sep 2026
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Sun, 06 Sep 2026
Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st
Fri, 04 Sep 2026
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 102 (M) |
| Shares Float | 100 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 102.8 (%) |
| Shares Short | 4,550 (K) |
| Shares Short P.Month | 5,330 (K) |
| EPS | 6.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 36.34 |
| Profit Margin | 20.9 % |
| Operating Margin | 22.1 % |
| Return on Assets (ttm) | 11.6 % |
| Return on Equity (ttm) | 22 % |
| Qtrly Rev. Growth | 39.5 % |
| Gross Profit (p.s.) | 21.44 |
| Sales Per Share | 33.15 |
| EBITDA (p.s.) | 8.98 |
| Qtrly Earnings Growth | 31.1 % |
| Operating Cash Flow | 898 (M) |
| Levered Free Cash Flow | 638 (M) |
| PE Ratio | 22.27 |
| PEG Ratio | 0.3 |
| Price to Book value | 4.18 |
| Price to Sales | 4.58 |
| Price to Cash Flow | 17.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|